Table 3: Comparative analysis between patients presenting with no nodules, benign nodules and thyroid carcinoma in Graves’ disease and Hashimoto’s thyroiditis.

Graves’ disease ( = 198) Hashimoto's thyroiditis ( = 77)
PTCBenignNo nodulePTCBenignNo nodule

Gender—male/female (%)1/9
(0.51/4.55)
3/43
(1.52/21.72)
14/128
(7.07/64.65)
0.8230/6
(0/7.79)
2/33
(2.6/42.86)
3/33
(3.9/42.86)
1
Age—yrs (range)39 (28–58)55.3 (27–84)43 (13–82.8)<0.001 c55 (51–84)55 (15–75)49.5 (17–79)0.556
Age at diagnosis—yrs (range)30 (17–49)48 (20–81)36 (9–77)<0.001 c49 (44–70)47 (5–65)43.5 (14–77)0.246
Disease duration—yrs (range)9 (3–18)5.5 (0.6–20)5.0 (0.5–5)0.0548.5 (2–14)6.7 (0.2–16)7 (0.1–21)0.91
Total thyroid volume—cc (range)55.1 (16.2–167.5)28.9 (4.1–242)23.1 (1.6–201.3)0.022 d26.7 (6.4–111.9)17.3 (1–74.1)9.8 (2.1–69.2)0.013 e
Time of followup—yrs (range)9 (3–18)5 (0.3–20)5 (0.1–20)0.04 d8.5 (3–14)6 (0.2–16)7 (0.1–21)0.842
Smoking (%)a4 (3.01)14 (10.53)49 (36.84)0.7571 (2.94)8 (23.53)5 (14.71)0.523
Time of treatment—yrs (range)3.5 (1–6)4 (0.3–17)3 (0.1–20)0.4167 (2–14)6 (1–16)7 (1–15)0.984
Number of nodules (range)1.5 (0–5)2 (1–7)NA0.641*3 (1–5)2 (1–6) NA0.037 *
Size of largest nodule on US—cm (range)2.2 (0.5–6.8)1.6 (0.7–5.7)NA0.172*2.1 (1–4.3)1.6 (0.5–4.6)NA0.234*
Ophthalmopathy (%)b5 (3.65)18 (13.14)69 (50.36)0.125NANANANA
Active disease (%)10 (5.05)41 (20.71)125 (63.13)0.507NANANANA
Radioiodine treatment (%)017 (8.59)49 (24.75)0.069NANANANA
99mTc uptake—% (range)11.9 (0.8–29)8.1 (0.2–82)10 (0.3–77)0.348NANANANA

a = 133 for GD and = 34 for HT.
b = 137 for GD.
cBenign versus no nodule and benign versus PTC.
dNo nodule versus PTC.
eBenign versus no nodule.
*Mann-Whitney test.
NA: not available.